New support to produce COVID-19 vaccines and treatments in Canada
Prime Minister Trudeau also announced investments to support vaccine, therapeutic, and biomanufacturing projects in Canada
OTTAWA — Prime Minister Justin Trudeau announced that the Government of Canada has signed a memorandum of understanding with Novavax to pursue the production of its COVID-19 vaccine at the National Research Council of Canada’s Biologics Manufacturing Centre in Montréal.
“Since the beginning of the pandemic, our top priority has been the health and safety of all Canadians,” Trudeau said in a prepared statement. “Today, we are investing in our biomanufacturing capacity so that we have the made-in-Canada vaccines and treatments we need to protect Canadians, now and in the future, and recover from the impacts of COVID-19.”
Trudeau also announced investments to support vaccine, therapeutic, and biomanufacturing projects in Canada. These include:
- Up to $25.1 million to Precision NanoSystems Incorporated (PNI), a Vancouver-based biotechnology company, to expand our ability to produce ribonucleic acid vaccines and future genetic medicines in Canada. PNI will build a $50.2 million biomanufacturing centre to produce vaccines and therapeutics for the prevention and treatment of diseases such as infectious diseases, rare diseases, cancer and other areas of unmet need.
- Up to $14 million to Edesa Biotech Inc. (Edesa), a biopharmaceutical company based in Markham, Ontario, to advance work on a monoclonal antibody therapy for acute respiratory distress syndrome, which is the leading cause of COVID-19 deaths. Edesa’s $18.7 million project has received Health Canada approval to conduct its phase 2 clinical trials, and has begun administering its treatment to clinical trial participants in Canada.
The Government of Canada’s actions are informed by the recommendations of the COVID-19 Vaccine and Therapeutics Task Forces and COVID-19 Joint Biomanufacturing Subcommittee.